Recombinant Human DRD5

Background

DRD5 is a G protein-coupled receptor of the D1-like dopamine receptor family that couples to Gs proteins, leading to activation of adenylate cyclase and an increase in cyclic AMP (cAMP) levels. DRD5 is highly expressed in limbic brain regions, including the hippocampus, hypothalamus, and cerebral cortex, where it modulates cognition, memory, and emotional behavior. DRD5 has a higher affinity for dopamine compared to DRD1, allowing it to regulate synaptic transmission and plasticity more effectively. It plays a key role in learning, working memory, and behavioral flexibility, with its dysfunction linked to schizophrenia, cognitive deficits, and neurological disorders. DRD5 is also involved in regulating motor function and reward pathways, contributing to the dopaminergic control of behavior. In peripheral tissues, DRD5 is expressed in renal, cardiovascular, and immune systems, where it regulates sodium balance, blood pressure, and immune cell activity. Dysregulation of DRD5 signaling has been associated with hypertension and autoimmune diseases. DRD5 is a potential therapeutic target for neuropsychiatric disorders, cognitive impairment, and cardiovascular dysfunction, given its role in dopamine-mediated signaling and cellular homeostasis.